Company intelligence / Profile preview

Lentigen Technology

Gaithersburg, Maryland, United Statesleadiq.com ↗

Ownership: Private
Development stage: Other

Overview

Lentigen Technology was a leading provider of GMP-compliant lentiviral vectors used in clinical-stage gene and cell therapies, supporting multiple partners’ programs including CAR-T cell immunotherapies. The company’s technology enabled efficient gene delivery for both research and commercial applications. It did not develop its own therapeutics but played a critical role in enabling advanced therapies to reach the clinic.

Therapeutic areas: Rare DiseasesOncology
Modalities: Gene therapyCell therapyViral vector
Industry: Non-Drug Biotech

Partnerships

Oncternal TherapeuticsTxCellWave BiotechThermoFisher ScientificThe National Institutes of HealthThe University of PennsylvaniaU.S. Army

Beyond the preview

Go deeper on Lentigen Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lentigen Technology.

Explore the full profile